Perimeter Solutions Valuation
Is PRM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PRM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PRM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PRM's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PRM?
Other financial metrics that can be useful for relative valuation.
| What is PRM's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$638.64m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 9.1x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does PRM's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 26.2x | ||
CCF Chase | 36.6x | n/a | US$1.2b |
ECVT Ecovyst | 18x | 33.5% | US$1.1b |
NGVT Ingevity | 11.8x | 32.1% | US$1.4b |
SCL Stepan | 38.3x | 43.8% | US$1.9b |
PRM Perimeter Solutions | 30.8x | n/a | US$638.6m |
Price-To-Earnings vs Peers: PRM is expensive based on its Price-To-Earnings Ratio (30.8x) compared to the peer average (26.2x).
Price to Earnings Ratio vs Industry
How does PRM's PE Ratio compare vs other companies in the US Chemicals Industry?
Price-To-Earnings vs Industry: PRM is expensive based on its Price-To-Earnings Ratio (30.8x) compared to the US Chemicals industry average (19.8x).
Price to Earnings Ratio vs Fair Ratio
What is PRM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 30.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PRM's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$4.11 | US$7.25 +76.4% | 37.9% | US$10.00 | US$4.50 | n/a | 2 |
| Dec ’24 | US$4.41 | US$7.25 +64.4% | 37.9% | US$10.00 | US$4.50 | n/a | 2 |
| Nov ’24 | US$2.92 | US$7.13 +144.0% | 40.4% | US$10.00 | US$4.25 | n/a | 2 |
| Oct ’24 | US$4.54 | US$9.50 +109.3% | 26.3% | US$12.00 | US$7.00 | n/a | 2 |
| Sep ’24 | US$5.91 | US$9.50 +60.7% | 26.3% | US$12.00 | US$7.00 | n/a | 2 |
| Aug ’24 | US$5.60 | US$9.50 +69.6% | 26.3% | US$12.00 | US$7.00 | n/a | 2 |
| Jul ’24 | US$6.15 | US$11.00 +78.9% | 9.1% | US$12.00 | US$10.00 | n/a | 2 |
| Jun ’24 | US$5.65 | US$11.00 +94.7% | 9.1% | US$12.00 | US$10.00 | n/a | 2 |
| May ’24 | US$7.42 | US$11.50 +55.0% | 4.3% | US$12.00 | US$11.00 | n/a | 2 |
| Apr ’24 | US$8.08 | US$13.00 +60.9% | 7.7% | US$14.00 | US$12.00 | n/a | 2 |
| Mar ’24 | US$8.71 | US$13.00 +49.3% | 7.7% | US$14.00 | US$12.00 | n/a | 2 |
| Feb ’24 | US$9.25 | US$13.00 +40.5% | 7.7% | US$14.00 | US$12.00 | n/a | 2 |
| Jan ’24 | US$9.14 | US$13.00 +42.2% | 7.7% | US$14.00 | US$12.00 | n/a | 2 |
| Dec ’23 | US$11.00 | US$13.00 +18.2% | 7.7% | US$14.00 | US$12.00 | US$4.41 | 2 |
| Nov ’23 | US$7.76 | US$13.00 +67.5% | 7.7% | US$14.00 | US$12.00 | US$2.92 | 2 |
| Oct ’23 | US$8.01 | US$13.00 +62.3% | 7.7% | US$14.00 | US$12.00 | US$4.54 | 2 |
| Sep ’23 | US$9.46 | US$14.25 +50.6% | 1.8% | US$14.50 | US$14.00 | US$5.91 | 2 |
| Aug ’23 | US$11.29 | US$14.25 +26.2% | 1.8% | US$14.50 | US$14.00 | US$5.60 | 2 |
| Jul ’23 | US$10.61 | US$14.25 +34.3% | 1.8% | US$14.50 | US$14.00 | US$6.15 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.